Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Type 2 diabetes

Pharmacologic Management of Type 2 Diabetes

(2013) William Harper et al.   Canadian Journal of Diabetes

We've Come a Long Way…Haven't We?

(2013) Michael Vallis   Canadian Journal of Diabetes

Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial

(2013) B. Charbonnel et al.   DIABETOLOGIA

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control

(2013) Helena Rodbard et al.   Endocrine Practice

Glucagonlike Peptide 1–Based Drugs and Pancreatitis: Clarity at Last, but What About Pancreatic Cancer?

(2013) Belinda Gier et al.   JAMA Internal Medicine

Glucagonlike Peptide 1–Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus

(2013) Sonal Singh et al.   JAMA Internal Medicine

A Retrospective Audit of Type 2 Diabetes Patients Prescribed Liraglutide in Real-Life Clinical Practice

(2013) Ciara M. Mulligan et al.   Diabetes Therapy

Recent advances in incretin-based therapies

(2012) David Russell-Jones et al.   CLINICAL ENDOCRINOLOGY

Efficacy and Safety of Switching From the DPP-4 Inhibitor Sitagliptin to the Human GLP-1 Analog Liraglutide After 52 Weeks in Metformin-Treated Patients With Type 2 Diabetes: A randomized, open-label trial

(2012) R. E. Pratley et al.   DIABETES CARE

 -Cell Function Preservation After 3.5 Years of Intensive Diabetes Therapy

(2012) L. B. Harrison et al.   DIABETES CARE

Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)

(2012) V. A. Fonseca et al.   DIABETES CARE

Exenatide Therapy and the Risk of Pancreatitis and Pancreatic Cancer in a Privately Insured Population

(2012) John A. Romley et al.   Diabetes Technology & Therapeutics

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETOLOGIA

Liraglutide Achieves A1C Targets More Often Than Sitagliptin or Exenatide when Added to Metformin in Patients with Type 2 Diabetes and a Baseline A1C

(2012) Allen King et al.   Endocrine Practice

Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial

(2012) Baptist Gallwitz et al.   LANCET

A Retrospective, Case-Note Survey of Type 2 Diabetes Patients Prescribed Incretin-Based Therapies in Clinical Practice

(2012) Marc Evans et al.   Diabetes Therapy

Effects of a 6-Month Exenatide Therapy on HbA1c and Weight in Korean Patients with Type 2 Diabetes: A Retrospective Cohort Study

(2012) Juyoung Shin et al.   Diabetes & Metabolism Journal

Contribution of insulin deficiency and insulin resistance to the development of type 2 diabetes: nature of early stage diabetes

(2011) Baptist Gallwitz et al.   ACTA DIABETOLOGICA

Treatment gaps in the management of cardiovascular risk factors in patients with type 2 diabetes in Canada

(2011) Manoela F.B. Braga et al.   CANADIAN JOURNAL OF CARDIOLOGY

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes

(2011) Robert Ratner et al.   Cardiovascular Diabetology

Exenatide bid observational study (ExOS): baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting

(2011) Richard M. Bergenstal et al.   CURRENT MEDICAL RESEARCH AND OPINION

Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes

(2011) Stuart A. Ross et al.   CURRENT MEDICAL RESEARCH AND OPINION

Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2—3 liraglutide clinical development studies

(2011) Steven P Marso et al.   Diabetes & Vascular Disease Research

Achieving a clinically relevant composite outcome of an HbA1c of

(2011) B. Zinman et al.   DIABETES OBESITY & METABOLISM

Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients

(2011) Giuseppe Derosa et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies

(2011) Michael Elashoff et al.   GASTROENTEROLOGY

One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial

(2011) R. Pratley et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

(2011) A Astrup et al.   INTERNATIONAL JOURNAL OF OBESITY

Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential

(2011) S. S. Torekov et al.   Obesity Reviews

Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetes

(2011) Kohei Kaku et al.   Journal of Diabetes Investigation

Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes

(2010) Y. Seino et al.   CURRENT MEDICAL RESEARCH AND OPINION

Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes

(2010) J. Rosenstock et al.   DIABETES CARE

Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies: A retrospective analysis of the LifeLink database

(2010) J. H. Best et al.   DIABETES CARE

Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes

(2010) A. Garber et al.   DIABETES OBESITY & METABOLISM

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

(2010) Richard E Pratley et al.   LANCET

Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis

(2010) Deepson S Shyangdan et al.   BMC Endocrine Disorders

Standards of Medical Care in Diabetes--2009

(2009)   DIABETES CARE

Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes: A randomized controlled trial exploring weekly, biweekly, and monthly dosing

(2009) J. Rosenstock et al.   DIABETES CARE

Secondary Failure of Metformin Monotherapy in Clinical Practice

(2009) J. B. Brown et al.   DIABETES CARE

One-Year Treatment With Exenatide Improves  -Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients: A randomized, controlled trial

(2009) M. C. Bunck et al.   DIABETES CARE

Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting

(2009) D. I. Brixner et al.   DIABETES OBESITY & METABOLISM

Global estimates of the prevalence of diabetes for 2010 and 2030

(2009) J.E. Shaw et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily

(2009) J. H. Best et al.   DIABETIC MEDICINE

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

(2009) M. Marre et al.   DIABETIC MEDICINE

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

(2009) John B Buse et al.   LANCET

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug—naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study

(2008) T MORETTO et al.   CLINICAL THERAPEUTICS

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study

(2008) M. Nauck et al.   DIABETES CARE

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

(2008) Alan Garber et al.   LANCET

10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes

(2008) Rury R. Holman et al.   NEW ENGLAND JOURNAL OF MEDICINE